This Undervalued Biotech Might Have Just Proven Its Star Drug's Staying Power

Benzinga_recent_news11-13

On Wednesday, Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) announced data from a post hoc analysis of the GALE extension study following five years of continuous treatment with Syfovre (pegcetacoplan ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2583402301?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/12/Medical-Research.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2025-11-13 02:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583402301","market":"us","top_or_hot":-1,"title":"This Undervalued Biotech Might Have Just Proven Its Star Drug's Staying Power","media":"Benzinga_recent_news","content":"<div>\n<p>On Wednesday, Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) announced data from a post hoc analysis of the GALE extension study following five years of continuous treatment with Syfovre (pegcetacoplan ...</p>\n\n<a href=\"https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/11/48814129/this-undervalued-biotech-might-have-just-proven-its-star-drugs-staying-power\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This Undervalued Biotech Might Have Just Proven Its Star Drug's Staying Power</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis Undervalued Biotech Might Have Just Proven Its Star Drug's Staying Power\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-13 02:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/11/48814129/this-undervalued-biotech-might-have-just-proven-its-star-drugs-staying-power><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>On Wednesday, Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) announced data from a post hoc analysis of the GALE extension study following five years of continuous treatment with Syfovre (pegcetacoplan ...</p>\n\n<a href=\"https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/11/48814129/this-undervalued-biotech-might-have-just-proven-its-star-drugs-staying-power\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4534","symbol_name":"瑞士信贷持仓","start_time":0,"source_url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/11/48814129/this-undervalued-biotech-might-have-just-proven-its-star-drugs-staying-power","article_id":"2583402301","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/12/Medical-Research.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/11/48814129/this-undervalued-biotech-might-have-just-proven-its-star-drugs-staying-power","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2583402301","pubTimestamp":1762972560,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Apellis reports five-year Syfovre data showing up to 31% slower GA lesion growth, reinforcing strong long-term efficacy and analyst optimism.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","BK4141":"半导体产品","LU0390134368.USD":"FRANKLIN GLOBAL GROWTH \"A\" (USD) ACC","LU0056508442.USD":"贝莱德世界科技基金A2","LU0823421333.USD":"BNP PARIBAS DISRUPTIVE TECHNOLOGY \"C\" (USD) ACC","BK4084":"特种房地产投资信托","BK4234":"特殊用途房地产信托","BK4529":"IDC概念","LU1043141396.HKD":"NINETY ONE GSF GLOBAL FRANCHISE \"A\" (HKD) ACC","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","BK4566":"资本集团","LU1852331112.SGD":"Blackrock World Technology Fund A2 SGD-H","LU2458330169.SGD":"FRANKLIN SHARIAH TECHNOLOGY \"A\" (SGD) ACC","BK4505":"高瓴资本持仓","LU1228905540.USD":"NINETY ONE GSF GLOBAL QUALITY DIVIDEND GROWTH \"A\" (USD) INC 2","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU2250418816.HKD":"BGF WORLD TECHNOLOGY \"A\" (HKD) ACC","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU0823434583.USD":"BNP PARIBAS US GROWTH \"C\" (USD) ACC","LU1861558580.USD":"日兴方舟颠覆性创新基金B","LU2458330243.SGD":"FRANKLIN SHARIAH TECHNOLOGY \"A-H1\" (SGDHDG) ACC","LU0109392836.USD":"富兰克林科技股A","LU1043141123.HKD":"NINETY ONE GSF GLOBAL FRANCHISE \"A\" (HKD) INC 2","LU0690374615.EUR":"FUNDSMITH EQUITY \"R\" (EUR) ACC","BK4614":"Manus概念股","LU0274383776.USD":"MANULIFE GF US SMALL CAP EQUITY \"AA\" (USD) INC","LU1951200564.SGD":"Natixis Thematics AI & Robotics Fund R/A SGD","PM":"菲利普莫里斯","LU2089985449.USD":"MANULIFE GF GLOBAL SEMICONDUCTOR OPPORTUNITIES \"AA\" (USD) ACC","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU1242518931.SGD":"Fullerton Lux Funds - Asia Absolute Alpha A Acc SGD","BK4605":"半导体精选","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1803068979.SGD":"FTIF - Franklin Technology A (acc) SGD-H1","LU0979878070.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"A\" (USD) ACC","LU0994945656.USD":"NINETY ONE GSF GLOBAL FRANCHISE \"A\" (USD) INC 2","LU1923623000.USD":"Natixis Thematics AI & Robotics Fund R/A USD","LU1989764664.SGD":"CPR Invest - Global Disruptive Opportunities A2 Acc SGD-H","IE00BMPRXR70.SGD":"Neuberger Berman 5G Connectivity A Acc SGD-H","LU1121112475.USD":"NINETY ONE GSF GLOBAL FRANCHISE \"A\" (USDHDG) ACC","APLS":"Apellis Pharmaceuticals Inc.","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","PW":"Power REIT","LU0265550946.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A5\" (USD) INC","BK4543":"AI","BK4512":"苹果概念","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU1066051811.HKD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (HKD) INC"},"translate_title":"这家被低估的生物技术公司可能刚刚证明了其明星药物的持久力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APLS":1,"PM":1,"PW":1.5},"content_text":"On Wednesday, Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) announced data from a post hoc analysis of the GALE extension study following five years of continuous treatment with Syfovre (pegcetacoplan injection) for geographic atrophy (GA) secondary to age-related macular degeneration (AMD).\nThe results demonstrate that both every-other-month and monthly Syfovre delayed GA lesion growth by approximately 1.5 years in patients with nonsubfoveal GA when compared to sham/projected sham.\nThe analysis showed that monthly pegcetacoplan patients experienced a 31% reduction in lesion growth over 60 months compared to projected sham, while those receiving pegcetacoplan every other month experienced a 27% reduction compared to projected sham.\nAlso Read: FDA Approval For Empaveli Marks Key Milestone In Apellis’ Rare Disease Portfolio\nWilliam Blair said the results are consistent with the prior four-year analysis, which showed 32% and 27% reductions, respectively.\nOver the five years, pegcetacoplan treatment effect translates to slowing lesion growth by roughly 16.5 months (PEOM) and 18.5 months (PM) compared to the projected sham. Analyst Lachlan Hanbury-Brown says the data reflect a meaningful slowing in disease progression and reinforce the durable efficacy of Syfovre.\nSyfovre total injection demand grew 4% quarter-over-quarter in the third quarter, with U.S. net product revenue of $150.9 million.\nWilliam Blair notes Apellis’ stock has been weak as the lack of copay assistance has curtailed Syfovre growth, despite a strong start to the Empaveli launch in C3G/IC-MPGN. The analyst views the weakness as a buying opportunity.\nAnalyst Hanbury-Brown says that Syfovre has blockbuster potential in GA over the long term, as its superior efficacy over competitor Astellas Pharma Inc.’s (OTC:ALPMF) (OTC:ALPMY) Izervay (avacincaptad pegol) should ultimately drive significant market share as physicians move beyond a focus on safety.\nSyfovre’s resilience in new patient share over the past year shows that this process is already underway, William Blair wrote on Wednesday.\nApellis trades at an enterprise value of less than 3 times the 2025 revenue estimate, which reflects a value disconnect as investors’ focus on the near-term competitive pressure on Syfovre overlooks the long-term outlook. William Blair rates shares Outperform.\nPrice Action: APLS stock was trading higher by 2.52% to $20.01 at last check Wednesday.\nRead Next:\nPhoto via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2583402301","isCrawlerRequest":true}